fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Brimonidine (02246284). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Brimonidine

All products: Limited Use (codes 171, 172, 387)

Alphagan P · DIN 02248151 · 0.15% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Alphagan P · DIN 02248151 Manufacturer: Allergan Inc.; listing date 2004-11-04 Health Canada: Marketed since 2023-11-28 · brand ALPHAGAN P · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.15 %/W/V · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248151)

Source record
DIN 02248151: Alphagan P Raw flags: sec12=Y, sec3=Y Item: 523600107; group id 614; item number 1580; lccId 00082; manufacturer id ALL Source form: Oph Sol; strength: 0.15% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.6017; ministry $2.0305 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248151 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72483
Interchangeable products
Brimonidine P · DIN 02301334 · $2.0305
Shortage status: resolved shortage (ended September 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248151
Shortage record checked October 6, 2026

Brimonidine P · DIN 02301334 · 0.15% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Brimonidine P · DIN 02301334 Manufacturer: A A Pharma Inc.; listing date 2008-10-01 Health Canada: Marketed since 2021-10-20 · brand BRIMONIDINE P · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.15 %/W/V · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Brimonidine P: Formulary list price $2.03 per unit (the source does not state the unit; exact figure $2.0305). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02301334)

Source record
DIN 02301334: Brimonidine P Raw flags: sec12=Y, sec3=Y Item: 523600107; group id 614; item number 1580; lccId 00082; manufacturer id AAP Source form: Oph Sol; strength: 0.15% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0305; ministry $2.0305 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02301334 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78666
Interchangeable products
Alphagan P · DIN 02248151 · $2.0305
Shortage status: active shortage (reported September 8, 2026, estimated to end October 16, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02301334
Shortage record checked October 6, 2026

Alphagan · DIN 02236876 · 0.2% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Alphagan · DIN 02236876 Manufacturer: Allergan Inc.; listing date 1998-12-31 Health Canada: Marketed since 2024-03-27 · brand ALPHAGAN · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02236876)

Source record
DIN 02236876: Alphagan Raw flags: sec12=Y, sec3=Y Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id ALL Source form: Oph Sol; strength: 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.7970; ministry $1.1550 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02236876 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60166
Interchangeable products
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550 Jamp-Brimonidine · DIN 02449226 · $1.1550 Med-Brimonidine · DIN 02507811 · $1.1550 Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: resolved shortage (ended September 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02236876
Shortage record checked October 6, 2026

Jamp-Brimonidine · DIN 02449226 · 0.2% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Brimonidine · DIN 02449226 Manufacturer: Jamp Pharma Corporation; listing date 2023-05-31 Health Canada: Marketed since 2026-01-21 · brand JAMP BRIMONIDINE · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Brimonidine: Formulary list price $1.16 per unit (the source does not state the unit; exact figure $1.1550). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449226)

Source record
DIN 02449226: Jamp-Brimonidine Raw flags: sec12=Y, sec3=Y Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id JPC Source form: Oph Sol; strength: 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1550; ministry $1.1550 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449226 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93504
Interchangeable products
Alphagan · DIN 02236876 · $1.1550 Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550 Med-Brimonidine · DIN 02507811 · $1.1550 Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: active shortage (reported September 15, 2026, estimated to end January 15, 2027, last updated September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449226
Shortage record checked October 6, 2026

Med-Brimonidine · DIN 02507811 · 0.2% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Brimonidine · DIN 02507811 Manufacturer: Generic Medical Partners Inc.; listing date 2022-03-31 Health Canada: Marketed since 2021-11-26 · brand MED-BRIMONIDINE · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Generic medical partners inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Med-Brimonidine: Formulary list price $1.16 per unit (the source does not state the unit; exact figure $1.1550). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02507811)

Source record
DIN 02507811: Med-Brimonidine Raw flags: sec12=Y, sec3=Y Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id GMP Source form: Oph Sol; strength: 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1550; ministry $1.1550 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02507811 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99720
Interchangeable products
Alphagan · DIN 02236876 · $1.1550 Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550 Jamp-Brimonidine · DIN 02449226 · $1.1550 Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: resolved shortage (ended November 15, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507811
Shortage record checked October 6, 2026

Sandoz Brimonidine · DIN 02305429 · 0.2% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Brimonidine · DIN 02305429 Manufacturer: Sandoz Canada Inc.; listing date 2008-08-28 Health Canada: Marketed since 2008-02-08 · brand SANDOZ BRIMONIDINE · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 % · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Brimonidine: Formulary list price $1.16 per unit (the source does not state the unit; exact figure $1.1550). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02305429)

Source record
DIN 02305429: Sandoz Brimonidine Raw flags: sec12=Y, sec3=Y Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id SDZ Source form: Oph Sol; strength: 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1550; ministry $1.1550 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02305429 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79097
Interchangeable products
Alphagan · DIN 02236876 · $1.1550 Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550 Jamp-Brimonidine · DIN 02449226 · $1.1550 Med-Brimonidine · DIN 02507811 · $1.1550
Shortage status: resolved shortage (ended March 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02305429
Shortage record checked October 6, 2026

Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · 0.2% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2026-06-19 — choose a marketed DIN from the same-category list.Discontinued June 19, 2026 · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2026-06-19 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below); Health Canada lists this DIN as Cancelled post market since 2026-06-19 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 Manufacturer: Teligent Canada Inc.; listing date 2022-01-31 Health Canada: Cancelled post market since 2026-06-19 · brand BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Hikma canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Brimonidine Tartrate Ophthalmic Solution: Formulary list price $1.16 per unit (the source does not state the unit; exact figure $1.1550). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02515377)

Source record
DIN 02515377: Brimonidine Tartrate Ophthalmic Solution Raw flags: sec12=Y, sec3=Y Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id TCI Source form: Oph Sol; strength: 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1550; ministry $1.1550 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02515377 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100476
Interchangeable products
Alphagan · DIN 02236876 · $1.1550 Jamp-Brimonidine · DIN 02449226 · $1.1550 Med-Brimonidine · DIN 02507811 · $1.1550 Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: discontinued (April 1, 2025, reported by HIKMA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02515377
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 19, 2026 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (S01E): coverage varies; not interchangeable

  • Acetazolamide: general benefit, not a benefit
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Methazolamide (Neptazane): general benefit, not a benefit
  • Timolol (Timoptic-XE): general benefit, not a benefit
  • Bimatoprost (Lumigan): limited Use 171, 172, 387, not a benefit

9 more in the class list below

Brimonidine tartrate & timolol maleate

All strengths: Limited Use, Reason for Use code 310, 393 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 310, 393 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

Apo-Brimonidine-Timop · DIN 02375311 · 0.2% & 0.5% · Oph Sol-10mL Pk

Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Brimonidine-Timop · DIN 02375311 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-09 · brand APO-BRIMONIDINE-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %, TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Brimonidine-Timop: Formulary list price $23.29 per unit (the source does not state the unit; exact figure $23.2900). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02375311)

Source record
DIN 02375311: Apo-Brimonidine-Timop Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id APX Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $23.2900; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375311 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86073
Interchangeable products
Combigan · DIN 09857298 · $23.2900 Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900
Shortage status: active shortage (reported December 16, 2025, estimated to end January 8, 2027, last updated September 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375311
Shortage record checked October 6, 2026

Jamp Brimonidine/Timolol · DIN 02531704 · 0.2% & 0.5% · Oph Sol-10mL Pk

Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Brimonidine/Timolol · DIN 02531704 Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31 Health Canada: Marketed since 2023-07-21 · brand JAMP BRIMONIDINE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V, BRIMONIDINE TARTRATE 0.2 %/W/V · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Brimonidine/Timolol: Formulary list price $23.29 per unit (the source does not state the unit; exact figure $23.2900). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531704)

Source record
DIN 02531704: Jamp Brimonidine/Timolol Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id JPC Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $23.2900; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531704 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102081
Interchangeable products
Apo-Brimonidine-Timop · DIN 02375311 · $23.2900 Combigan · DIN 09857298 · $23.2900
Shortage status: active shortage (reported March 12, 2026, estimated to end November 6, 2026, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531704
Shortage record checked October 6, 2026

Combigan · PIN 09857298 · 0.2% & 0.5% · Oph Sol-10mL Pk

Limited Use, Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692

Check Health Canada brand DIN
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Combigan (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Combigan · DIN 09857298 Manufacturer: Allergan Inc.; listing date 2008-08-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692
Re-check Health Canada status and shortages (live)

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857298)

Source record
DIN 09857298: Combigan Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id ALL Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $46.5800; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857298 Health Canada record for this brand: DIN 02248347 (Marketed, December 13, 2023) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692
Interchangeable products
Apo-Brimonidine-Timop · DIN 02375311 · $23.2900 Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857298
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01E): coverage varies; not interchangeable

  • Acetazolamide: general benefit, not a benefit
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Methazolamide (Neptazane): general benefit, not a benefit
  • Timolol (Timoptic-XE): general benefit, not a benefit
  • Bimatoprost (Lumigan): limited Use 171, 172, 387, not a benefit

9 more in the class list below

Brinzolamide & brimonidine tartrate

All products: Limited Use (codes 393, 466)

Simbrinza · DIN 02435411 · 1.0% & 0.2% · Oph suspension-10mL Pk

Limited Use, Reason for Use code 466, 393 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 466, 393 required
Write on scriptone applicable Reason for Use code, 466 or 393 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 466, 393
Reason for Use code 466 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with brinzolamide or brimonidine. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Simbrinza · DIN 02435411 Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-10-29 Health Canada: Marketed since 2018-04-18 · brand SIMBRINZA · ATC S01EC54 BRINZOLAMIDE, COMBINATIONS, S01EC54 BRINZOLAMIDE, COMBINATIONS · form Suspension · route Ophthalmic · ingredients BRINZOLAMIDE 1 %/W/V, BRIMONIDINE TARTRATE 0.2 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Simbrinza: Formulary list price $50.69 per unit (the source does not state the unit; exact figure $50.6900). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435411)

Source record
DIN 02435411: Simbrinza Raw flags: sec12=Y, sec3=Y Item: 523600143; group id 617; item number 1584; lccId 00258; manufacturer id NOV Source form: Oph Susp-10mL Pk; strength: 1.0% & 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.6900; ministry $50.6900 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435411 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91973
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435411
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01E): coverage varies; not interchangeable

  • Acetazolamide: general benefit, not a benefit
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Methazolamide (Neptazane): general benefit, not a benefit
  • Timolol (Timoptic-XE): general benefit, not a benefit
  • Bimatoprost (Lumigan): limited Use 171, 172, 387, not a benefit

9 more in the class list below

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL

· 5 products · Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk

LATANOPROST

· 9 products · Limited Use, codes 171, 172, 387 · strengths: 0.005% · Oph Sol-2.5mL Pk

LATANOPROST & TIMOLOL MALEATE

· 9 products · Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:36 and 18 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: intraocular pressure, open-angle glaucoma or ocular hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. LATANOPROST · Limited Use, codes 171, 172, 387 1 INDICATIONS XALATAN (latanoprost) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00077198.PDF; date SEP 25, 2024; DIN 02231493; fetched 2026-09-10 Product monograph LATANOPROSTENE BUNOD · Limited Use, codes 171, 172, 387 1 INDICATIONS VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00048990.PDF; date December 27, 2018; DIN 02484218; fetched 2026-09-10 Product monograph TRAVOPROST · Limited Use, codes 171, 172, 387 INDICATIONS AND CLINICAL USE Sandoz Travoprost is indicated for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00051001.PDF; date May 7, 2019; DIN 02413167; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS ALPHAGAN® (brimonidine tartrate) is indicated for:  the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of ALPHAGAN has not been established in pediatric patients; therefore, Health Canada has not authorized an indication for pediatric use. Several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% in pediatric populations. See 2 CONTRAINDICATIONS, 7.1.3 Pediatrics and 8.2.1 Clinical Trial Adverse Reactions – Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): No overall difference in safety and effectiveness has been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00067621.PDF PM date: NOV 24, 1997 Source product: ALPHAGAN; DIN 02236876; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS APO-BRIMONIDINE-TIMOP (brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate)) ophthalmic solution is indicated for: • the control of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND when the use of brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution is considered appropriate. • reduction of long term fluctuation in IOP. In addition to controlling IOP, brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution reduces long term variability, or fluctuation, in IOP. Together, reductions in IOP and in IOP fluctuation are expected to slow the progression of visual field loss in patients with glaucoma. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Based on evidence from clinical studies and experience, use in the geriatric population is not associated with any differences… https://pdf.hres.ca/dpd_pm/00070296.PDF PM date: December 14, 2022 Source product: APO-BRIMONIDINE-TIMOP; DIN 02375311; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS SIMBRINZA (brinzolamide / brimonidine tartrate ophthalmic suspension) is indicated for: • the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction AND when the use of SIMBRINZA is considered appropriate. 1.1 Pediatrics Paediatrics (< 18 years of age): The safety and efficacy of SIMBRINZA has not been established in pediatric patients; therefore, Health Canada has not authorized an indication for pediatric use. Several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% in pediatric populations. (see 2 CONTRAINDICATIONS and 7.1.3, Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00068869.PDF PM date: DEC 23, 2022 Source product: SIMBRINZA; DIN 02435411; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Brimonidine P · DIN 02301334 Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-16, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02301334

Check this DIN again

Jamp-Brimonidine · DIN 02449226 Shortage status: active shortage (reported 2026-09-15, estimated to end 2027-01-15, last updated 2026-09-22); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449226

Check this DIN again

Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 Shortage status: discontinued (2025-04-01, reported by HIKMA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02515377

Check this DIN again

Apo-Brimonidine-Timop · DIN 02375311 Shortage status: active shortage (reported 2025-12-16, estimated to end 2027-01-08, last updated 2026-09-04); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375311

Check this DIN again

Jamp Brimonidine/Timolol · DIN 02531704 Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-11-06, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531704

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18